ZITUVIMET Drug Patent Profile

Which patents cover Zituvimet, and what generic alternatives are available?

Zituvimet is a drug marketed by Zydus Lifesciences and is included in two NDAs.

The generic ingredient in ZITUVIMET is metformin hydrochloride; sitagliptin. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin profile page.

Summary for ZITUVIMET

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Drug Prices:	Drug price information for ZITUVIMET
What excipients (inactive ingredients) are in ZITUVIMET?	ZITUVIMET excipients list
DailyMed Link:	ZITUVIMET at DailyMed

See drug prices for ZITUVIMET

Pharmacology for ZITUVIMET

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

US Patents and Regulatory Information for ZITUVIMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Lifesciences	ZITUVIMET	metformin hydrochloride; sitagliptin	TABLET;ORAL	216743-002	Nov 3, 2023		RX	Yes	Yes
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778-003	Jul 18, 2024		RX	Yes	Yes
Zydus Lifesciences	ZITUVIMET	metformin hydrochloride; sitagliptin	TABLET;ORAL	216743-001	Nov 3, 2023		RX	Yes	No
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778-002	Jul 18, 2024		RX	Yes	No
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778-001	Jul 18, 2024		RX	Yes	No

EU/EMA Drug Approvals for ZITUVIMET

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Ristfor	sitagliptin, metformin hydrochloride	EMEA/H/C/001235For patients with type-2 diabetes mellitus:Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.Ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	no	no	no	2010-03-15
Accord Healthcare S.L.U.	Sitagliptin / Metformin hydrochloride Accord	sitagliptin, metformin hydrochloride	EMEA/H/C/005850For adult patients with type 2 diabetes mellitus:It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	yes	no	no	2022-07-22
Sun Pharmaceutical Industries Europe B.V.	Sitagliptin / Metformin hydrochloride Sun	sitagliptin, metformin hydrochloride	EMEA/H/C/005778For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride SUN is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Sitagliptin/Metformin hydrochloride SUN is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Sitagliptin/Metformin hydrochloride SUN is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.Sitagliptin/Metformin hydrochloride SUN is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.	Authorised	yes	no	no	2023-03-31

Last updated: July 2, 2026

Zituvimet (Zituvimet) market dynamics and financial trajectory: sales, payer access, competition, and exclusivity

Zituvimet’s market dynamics are primarily shaped by (1) oncology- and payer-driven access constraints typical for specialty launches, (2) competitive pressure from existing standard-of-care and pipeline entrants, and (3) the durability of IP and regulatory exclusivity for the specific active ingredient(s) and formulation(s) used in Zituvimet. Zituvimet’s financial trajectory will track the rate of uptake in target indications, net price erosion from rebates and contract carve-outs, and loss of protection events that drive generic and biosimilar entry risk.

What follows is a data-grounded market-and-financial trajectory framework for Zituvimet. If any of the underlying identifiers (active ingredient, NDA/BLA number, manufacturer, launch year, indications, or geography) are not uniquely determined, the result cannot be completed accurately.

What is Zituvimet and what drives its revenue model?

Featured snippet: Zituvimet’s revenue model depends on its covered indication set, the specialty distribution channel it uses (buy-and-bill vs. specialty pharmacy), and the net-price components (WAC, rebates, patient assistance, and contract terms) tied to payer policy.

Commercial structure: specialty channel and reimbursement logic

• Care setting: determines whether Zituvimet is typically administered in hospital/infusion centers (buy-and-bill) or dispensed through specialty pharmacies (contract pharmacy networks).
• Coding and billing: revenue depends on whether reimbursement is dominated by:
  • diagnosis-related payment adjustments,
  • drug pass-through or APC/DRG mechanics, or
  • payer-specific utilization management.
• Utilization management:
  • prior authorization,
  • step edits,
  • site-of-care restrictions,
  • formulary tiering.

Net pricing drivers

For specialty products, “financial trajectory” is usually better explained by net price rather than list price:

• rebate and discount programs tied to volume,
• oncology contracting behavior (indication-based and line-of-therapy terms),
• patient assistance costs that offset affordability gaps.

How have Zituvimet sales performed since launch?

Featured snippet: A complete sales trajectory requires verified post-launch commercial reporting (company filings, IQVIA/NPD, or public market data), plus indication-level segmentation.

Sales trajectory components

A typical specialty product’s quarterly pattern reflects:

• early uptake volatility after launch,
• payer formulary decisions (restrictive → broader access),
• distribution ramp and inventory normalization,
• competitive shocks from competitor launches and guideline updates.

What to measure for trend confirmation

• Unit growth by indication and line of therapy
• Net sales vs. estimated demand
• Gross-to-net change over time (rebates, chargebacks, returns)
• Geographic mix (US vs. ex-US rollouts)

What patent and regulatory factors determine Zituvimet’s financial runway?

Featured snippet: Zituvimet’s sales durability is driven by the exclusivity regime for its specific active ingredient(s), indication(s), and approved dosage form, plus any Orange Book blocking patents and pediatric/extra exclusivity extensions.

How to map protection to revenue

Protection typically breaks into:

• Regulatory exclusivity:
  • New Chemical Entity (NCE) or New Therapeutic Biological Product (for biologics),
  • 5-year MA exclusivity,
  • pediatric exclusivity extensions where applicable.
• Patent estate:
  • composition of matter,
  • method-of-use,
  • formulation and dosing regimens,
  • manufacturing/process.

Patent strength indicators that affect valuation

• breadth of claims across indications,
• claim stagger (blocking vs. non-blocking),
• likelihood of Paragraph IV challenges,
• settlement outcomes.

Orange Book status and FDA exclusivity

A complete exclusivity timeline requires the drug’s NDA/BLA number and its Orange Book listings (patent numbers and expiration dates), plus FDA approval history for exclusivity start dates.

When does Zituvimet lose exclusivity and face generic or biosimilar risk?

Featured snippet: Generic or biosimilar exposure depends on the expiration of the last unexpired FDA-listed patent(s) and regulatory exclusivity, and on whether patents are “blocking” for the specific dosage form and indication.

Generic entry risk mechanics

• Paragraph IV (Hatch-Waxman):
  • triggers 180-day exclusivity for the first filer,
  • depends on whether the ANDA is carved to a specific strength or indication.
• Formulation and method-of-use barriers:
  • even after composition patent expiry, method-of-use and formulation patents can delay full substitution.

Biosimilar risk mechanics (if applicable)

If Zituvimet is a biologic or depends on biologic mechanisms:

• biosimilar pathway eligibility depends on reference product, interchangeability status requirements, and any continuing reference product exclusivities.

Which competitors threaten Zituvimet’s market share?

Featured snippet: Competitors are primarily differentiated by clinical outcomes, payer preference (formulary and step therapy), and dosing or administration convenience.

Competitive pressure categories

1. Therapeutic alternatives already on formulary
   • guideline-endorsed agents with entrenched payer positioning.
2. New entrants in the same line of therapy
   • head-to-head label expansions,
   • new safety or efficacy differentiators.
3. “De facto” competition from care pathways
   • shifts in treatment sequencing that reduce addressable patients for Zituvimet.

How market share loss usually shows up

• sudden deceleration in new patient starts,
• increased use of alternative brands with similar endpoints,
• stronger rebate pressure and price concessions.

What is the financial trajectory under best-case, base-case, and downside entry scenarios?

Featured snippet: Financial trajectory is bounded by (1) time to broad payer coverage and (2) time until patent or exclusivity loss enabling substitution.

Best-case scenario

• sustained payer access expansion,
• limited competitive encroachment,
• slower net price deterioration from continued contracting leverage.

Base-case scenario

• stable growth early,
• moderate net price erosion as competitors enter,
• gradual uptake shift by indication/line-of-therapy.

Downside scenario

• earlier-than-expected formulary restriction,
• rapid contract tightening and rebate growth,
• IP loss leading to earlier generic/biosimilar uptake.

What Zituvimet-specific litigation and settlement dynamics affect expected cash flows?

Featured snippet: Paragraph IV litigation timing and settlement terms determine whether generics/biosimilars enter after a “design-around” or at a later protected timepoint.

What matters most in Paragraph IV disputes

• court rulings on blocking patents,
• appeal timelines,
• settlement date and effective entry date,
• scope of “carve-outs” (indications, strengths, patient populations).

Why settlement terms move valuation

• earlier settlement entry dates accelerate price erosion,
• delayed entry extends peak sales and post-peak franchise value.

What is the FDA regulatory status of Zituvimet and what does it imply for uptake?

Featured snippet: FDA approval pathway and label breadth affect uptake through physician confidence, payer coverage decisions, and eligibility for line-of-therapy usage.

Label and access implications

• broader label = more patient eligible = faster uptake,
• narrower label = slower penetration, more prior authorization scrutiny,
• safety communications can change persistence and dosing adherence.

What formulations are protected by patents and how does that shape substitution risk?

Featured snippet: If Zituvimet’s formulation and dosing regimen are patented, substitution can be delayed even when the base composition is no longer protected.

Substitution timing depends on claim coverage

• Composition expiry alone does not guarantee substitution.
• Formulation and process patents can require different excipients, manufacturing steps, or stability profiles.
• Method-of-use patents can constrain ANDA labeling to avoid infringement.

How does Zituvimet compare with other specialty drugs in its market segment?

Featured snippet: Zituvimet’s market performance should be benchmarked on (1) time-to-payer broad access and (2) net price trajectory relative to comparators.

Benchmark metrics

• share of eligible patients treated,
• persistence and dose intensity (if applicable),
• gross-to-net trend,
• percentage of volume under preferred formulary terms.

Key Takeaways

• Zituvimet’s financial trajectory is primarily governed by the timing and scope of regulatory exclusivity and Orange Book blocking patents, plus payer access dynamics that determine net pricing and persistence.
• Generic or biosimilar risk will materialize when the last relevant protection for the specific strength and indication set expires, and when Paragraph IV litigation or settlements do not delay entry.
• Competitive pressure will show up first in net price erosion and treatment switching, then in unit growth deceleration.
• A complete, numbers-based sales and cash-flow projection requires verified Zituvimet identifiers (active ingredient(s), NDA/BLA number, approved indications, manufacturer, geography) and confirmed Orange Book patent tables and expiration dates; without those, the trajectory cannot be stated with precision.

FAQs

1. What Orange Book patents cover Zituvimet and which are blocking?
2. When is the earliest possible generic or biosimilar launch date for Zituvimet by strength and indication?
3. How do prior authorization and step edits typically affect specialty drug net sales for products like Zituvimet?
4. What settlement patterns most often determine whether early filers win Paragraph IV exclusivity for drugs like Zituvimet?
5. How does label breadth and FDA pathway designation influence payer formulary inclusion and prescribing adoption for Zituvimet?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Current database). https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-02)
2. FDA. Drug Approval Reports / Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-02)